



Version of attached le:
Published Version
Peer-review status of attached le:
Peer-reviewed
Citation for published item:
Maier, Rebecca and Bawamia, Bilal and Bennaceur, Karim and Dunn, Sarah and Marsay, Leanne and Amoah,
Roland and Kasim, Adetayo and Filby, Andrew and Austin, David and Hancock, Helen and Spyridopoulos,
Ioakim (2020) 'Telomerase activation to reverse immunosenescence in elderly patients with acute coronary
syndrome : protocol for a randomized pilot trial.', JMIR research protocols., 9 (9). e19456.
Further information on publisher's website:
https://doi.org/10.2196/19456
Publisher's copyright statement:
c©Rebecca Maier, Bilal Bawamia, Karim Bennaceur, Sarah Dunn, Leanne Marsay, Roland Amoah, Adetayo Kasim,
Andrew Filby, David Austin, Helen Hancock, Ioakim Spyridopoulos. Originally published in JMIR Research Protocols
(http://www.researchprotocols.org), 23.09.2020. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work, rst published in JMIR Research
Protocols, is properly cited. The complete bibliographic information, a link to the original publication on
http://www.researchprotocols.org, as well as this copyright and license information must be included.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-prot purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
https://dro.dur.ac.uk
Protocol
Telomerase Activation to Reverse Immunosenescence in Elderly
Patients With Acute Coronary Syndrome: Protocol for a
Randomized Pilot Trial
Rebecca Maier1, MSc; Bilal Bawamia2, MBBS, MRCP; Karim Bennaceur3, PhD; Sarah Dunn1, MSc; Leanne Marsay1,
PhD; Roland Amoah3, MBBS; Adetayo Kasim4, PhD; Andrew Filby5, PhD; David Austin2, MD, FRCP; Helen
Hancock1, PhD; Ioakim Spyridopoulos3, MD, FRCP
1Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, United Kingdom
2James Cook University Hospital, Middlesbrough, United Kingdom
3Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom
4Wolfson Research Institute for Health and Wellbeing, Durham University, Durham, United Kingdom
5Flow Cytometry Core Facility, Newcastle University, Newcastle Upon Tyne, United Kingdom
Corresponding Author:
Ioakim Spyridopoulos, MD, FRCP








Background: Inflammation plays a key role in the pathophysiology of coronary heart disease (CHD) and its acute manifestation,
acute coronary syndrome (ACS). Aging is associated with a decline of the immune system, a process known as immunosenescence.
This is characterized by an increase in highly proinflammatory T cells that are involved in CHD progression, plaque destabilization,
and myocardial ischemia–reperfusion injury. Telomere dysfunction has been implicated in immunosenescence of T lymphocytes.
Telomerase is the enzyme responsible for maintaining telomeres during cell divisions. It has a protective effect on cells under
oxidative stress and helps regulate flow-mediated dilation in microvasculature.
Objective: The TACTIC (Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome) trial will
investigate whether a telomerase activator, TA-65MD, can reduce the proportion of senescent T cells in patients with ACS with
confirmed CHD. It will also assess the effect of TA-65MD on decreasing telomere shortening, reducing oxidative stress, and
improving endothelial function.
Methods: The study was designed as a single-center, randomized, double-blind, parallel-group, placebo-controlled phase II
trial. Recruitment started in January 2019. A total of 90 patients, aged 65 years or older, with treated ACS who have had CHD
confirmed by angiography will be enrolled. They will be randomized to one of two groups: TA-65MD oral therapy (8 mg twice
daily) or placebo taken for 12 months. The primary outcome is the effect on immunosenescence determined by a decrease in the
proportion of CD8+ TEMRA (T effector memory cells re-expressing CD45RA [CD45 expressing exon A]) cells at 12 months.
Secondary outcomes include leukocyte telomere length, endothelial function, cardiac function as measured by echocardiography
and NT-proBNP (N-terminal fragment of the prohormone brain-type natriuretic peptide), systemic inflammation, oxidative stress,
and telomerase activity.
Results: The study received National Health Service (NHS) ethics approval on August 9, 2018; Medicines and Healthcare
products Regulatory Agency approval on October 19, 2018; and NHS Health Research Authority approval on October 22, 2018.
The trial began recruiting participants in January 2019 and completed recruitment in March 2020; the trial is due to report results
in 2021.
Conclusions: This pilot trial in older patients with CHD will explore outcomes not previously investigated outside in vitro or
preclinical models. The robust design ensures that bias has been minimized. Should the results indicate reduced frequency of
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immunosenescent CD8+ T cells as well as improvements in telomere length and endothelial function, we will plan a larger,
multicenter trial in patients to determine if TA-65MD is beneficial in the treatment of CHD in elderly patients.
Trial Registration: ISRCTN Registry ISRCTN16613292; http://www.isrctn.com/ISRCTN16613292 and European Union Drug
Regulating Authorities Clinical Trials Database (EudraCT), European Union Clinical Trials Register 2017-002876-26;
https://tinyurl.com/y4m2so8g
International Registered Report Identifier (IRRID): DERR1-10.2196/19456
(JMIR Res Protoc 2020;9(9):e19456) doi: 10.2196/19456
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Introduction
Background
Inflammation plays a key part in the pathophysiology of
coronary heart disease (CHD) and its acute manifestation—acute
coronary syndrome (ACS)—from atheroma formation to plaque
rupture [1]. Despite contemporary treatment, recurrent adverse
events (AEs) post-ACS remain common, especially in the
elderly [2]. Aging is associated with a decline of the immune
system, a process known as immunosenescence [3], leading to
an increased burden of disease. Targeting interleukin 1 (IL-1β),
the principal cytokine of innate immunity, in patients with
previous myocardial infarction (MI) has been shown to reduce
subsequent adverse cardiovascular outcomes [4]. Furthermore,
the contribution of the adaptive immune system to the complex
inflammatory response evoked during ACS has been
demonstrated extensively in experimental and clinical studies
[5]. In particular, highly proinflammatory senescent T cells are
thought to be key players in plaque destabilization [6] and
myocardial ischemia–reperfusion injury [7].
Telomere dysfunction has been implicated in immunosenescence
of T cells [3,8]. Telomeres are DNA caps that protect the ends
of chromosomal DNA. They are widely regarded as the internal
biological clock of a living organism and shorten by a few base
pairs with every cell division. This process can be slowed down
by activation of telomerase, which is responsible for producing
and maintaining telomeres. Shorter lymphocyte telomeres are
associated with development of CHD as well as increased
cardiovascular risk and mortality independent of conventional
vascular risk factors [9-12]. Alleles associated with shorter
telomere length (TL) were also associated with an increased
risk of CHD, suggesting a causal relationship [13].
The TACTIC (Telomerase ACTivator to reverse
Immunosenescence in Acute Coronary Syndrome) trial was
designed to test whether a telomerase activator can reduce the
proportion of senescent T cells in patients following ACS. There
is accumulating evidence that telomerase, through its telomerase
reverse transcriptase (TERT) catalytic subunit, contributes to
cell physiology independently of its ability to elongate
telomeres. We and our collaborators have demonstrated the
effect of oxidative stress on telomerase as well as a
telomere-independent protective effect of telomerase in cells
under oxidative stress [14,15]. Telomerase activity (TA) has
also been shown to regulate endothelial flow-mediated dilation
(FMD) [16].
The small molecule cycloastragenol (CAG), isolated from the
roots of the herb astragalus, is the only available telomerase
activator in humans. TA-65MD is a purified and encapsulated
form of CAG with increased bioavailability (T.A. Sciences).
We have also shown that TA-65MD induces telomerase and
proliferation in CD4 T lymphocytes in a TERT-dependent way
[17]. In a randomized controlled trial investigating
cytomegalovirus (CMV)-positive healthy subjects aged 53-87
years old, subjects taking 8 mg of TA-65MD daily increased
TL over the 12-month period, whereas subjects in the placebo
group significantly lost TL [18].
Trial Rationale
The evidence indicates that telomerase deficiency in
atherosclerosis leads to accelerated immunosenescence with
telomere shortening in peripheral blood leukocytes, increased
oxidative stress and inflammation, and impaired microvascular
endothelial function, all of which contribute to CHD
progression. We hypothesize that activating telomerase with
TA-65MD will lead to reduced immunosenescence, decreased
telomere shortening, and improved endothelial function in
patients with CHD. The null hypothesis is that there will be no
difference in immunosenescence between the two groups
following 12 months of treatment with TA-65MD or placebo.
The choice of active treatment versus placebo is appropriate in
this population where no telomerase activator is currently used




We aim to assess the effect of 8 mg of oral TA-65MD given
twice daily for 12 months on immunosenescence in older
patients following ACS.
Secondary Objectives
The secondary objectives of this trial are as follows:
1. To investigate the effect of 1-year TA-65MD treatment on
leukocyte TL.
2. To investigate the effect of 1-year TA-65MD treatment on
microvascular endothelial function.
3. To investigate the effect of 1-year TA-65MD treatment on
systemic inflammation and heart failure, reflected by
expression of N-terminal fragment of the prohormone
brain-type natriuretic peptide (NT-proBNP) and
high‐sensitivity C‐reactive protein (hsCRP).
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4. To investigate the effect of 1-year TA-65MD treatment on
measures of cardiac function as measured by
echocardiography.
5. To investigate the effect of TA-65MD treatment on TA and
oxidative stress.
6. To investigate the effect of TA-65MD treatment on clinical
events—all-cause death, stroke, or MI—in patients after 1
year.
7. To characterize the AE profile of TA-65MD.
8. To quantify adherence to study drugs.
9. To investigate the impact of seropositivity to CMV at
baseline on trial outcomes.
Methods
Trial Design
This is a single-center, randomized, double-blind, parallel-group,
placebo-controlled phase II trial comparing TA-65MD with
placebo in 90 participants with CHD who have had ACS in the
6 months prior to consent. A total of 90 patients will be
randomized to either the TA-65MD group (n=45) or the placebo
group (n=45); TA-65MD and placebo will be taken by these
groups, respectively, twice daily for 12 months. The schedule
of this trial is shown in Table 1. The trial will run according the
International Conference on Harmonisation (ICH)-Good Clinical
Practice (GCP) and in accordance with relevant UK legislation
and the trial protocol. This trial was registered at the
International Standard Randomized Controlled Trial Number
(ISRCTN) registry (16613292) and at the European Union Drug
Regulating Authorities Clinical Trials Database (EudraCT),
European Union Clinical Trials Register (2017-002876-26).
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Table 1. Trial schedule of assessments and interventions.


















XPhysical assessment of height and weight
XVenous sample (5 mL) cytomegalovirus
IgGb
XXXVenous sample (4 mL) CD8 TEMRAc
immunosenescence (primary outcome)d
XXXVenous sample (36 mL) CD8 and CD4
immunosenescence (secondary out-
comes), telomere length, and telomerase
activity
XXXVenous sample (4 mL) oxidative stress,
future use
XXXVenous sample (5 mL) future research
use—optional consent
XXXVenous sample (5mL) hsCRPe and NT-
proBNPf





XXXXXXDispensing of investigational medicinal
product (IMP)
XXXXXReturn of unused IMP and drug adher-
ence
XXXXXAdverse events evaluation
aBaseline assessments are completed after written consent is obtained and are performed before randomization.
bIgG: immunoglobulin G.
cTEMRA: T effector memory cells re-expressing CD45RA (CD45 expressing exon A).
dResults from baseline immunosenescence sample are required for randomization.
ehsCRP: high‐sensitivity C‐reactive protein.
fNT-proBNP: N-terminal fragment of the prohormone brain-type natriuretic peptide.
Primary Outcome
The primary outcome is immunosenescence following 12
months of treatment with TA-65MD. Immunosenescence will
be determined by flow cytometry and fluorescence-activated
cell sorting (FACS) (see Figure 1); the proportion of terminally
differentiated CD8+ effector memory cells (% CD8+ TEMRA
[T effector memory cells re-expressing CD45RA (CD45
expressing exon A)]) will be calculated from the total number
of peripheral blood CD8+ T lymphocytes. We have previously
demonstrated the prognostic utility of CD8+ TEMRA as a
measure for immunosenescence [19]. The mean difference
between the intervention and control arms will be compared at
12 months.
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Figure 1. Example gating path for seven-color fluorescence-activated cell sorting (FACS) from ethylenediaminetetraacetic acid (EDTA) peripheral
blood. AF700: Alexa Fluor 700; APC: allophycocyanin; BV421: Brillian Violet 421; CCR7: C-C chemokine receptor type 7; CD45RA: CD45 expressing
exon A; CM: central memory; CX3CR1: C-X3-C motif chemokine receptor 1; EM: effector memory; FITC: fluorescein isothiocyanate; FSC: forward
scatter; FSC-H: forward scatter-pulse height; PE: phycoerythrin; PE-Cy7: phycoerythrin and cyanine 7; SSC: side scatter; TEMRA: T effector memory
cells re-expressing CD45RA; V500: violet 500.
Secondary Outcomes
CD8 T Cell Telomere Length
TL will be determined from cryopreserved peripheral blood
mononuclear cells (PBMCs) by flow cytometry-fluorescent in
situ hybridization (flow-FISH) [9]. TL will be measured in total
leukocytes and CD8+ T cells. CD8+ T cell TL is significantly
reduced in patients with CHD and post-MI [9]. We expect TL
in CD8+ T cells to decrease less in patients treated with
TA-65MD. TL will be measured in total leukocytes and in CD8+
T cells at baseline, 6 months, and 12 months.
Microvascular Endothelial Function
Microvascular endothelial function will be assessed by
measuring FMD at baseline, 6 months, and 12 months. Using
plethysmography at the fingertips of both hands, the EndoPAT
(Peripheral Arterial Tone) system (Itamar Medical Ltd) will
calculate an index of pulse wave amplitude after cuff occlusion
to before occlusion of the test arm divided by the same ratio of
the control arm, namely the reactive hyperemic index. FMD
has been shown to be compromised in patients with CHD and
microvascular dysfunction as a predictor of adverse clinical
outcome [20].
Systemic Inflammation
Systemic inflammation will be assessed using the hsCRP, which
is a downstream biomarker of inflammation associated with an
increased risk of cardiovascular events [21].
Cardiac Function
Cardiac function will be assessed by NT-proBNP and
transthoracic echocardiography at baseline and 12 months.
Together, these measures will determine myocardial function,
strain (NT-proBNP), and global longitudinal strain, reflecting
the pathophysiological targets of heart failure. Lack of
telomerase and presence of shortened telomeres in
cardiomyocytes from preclinical models (ie, mice) have been
shown to be critical in the development of heart failure in that
species [22]. Patients with chronic heart failure have shorter TL
compared to age- and gender-matched controls with incremental
attrition according to the presence and extent of coronary artery
disease (CAD) [23].
Telomerase Activity
TA will be assessed by a modified telomeric repeat amplification
protocol (TRAP) assay, using digital droplet polymerase chain
reaction (PCR) [24,25]. This provides an indication of drug
effect: TA-65MD is expected to increase TA in PBMCs.
Oxidative Stress
Oxidative stress will be measured with the thiobarbituric acid
reactive substances (TBARS) colorimetric assay (Oxford
Biomedical Research) from freshly collected and cryopreserved
plasma. TBARS is an established assay to quantify lipid
peroxides [26].
Seropositivity to Cytomegalovirus
The effect of CMV seropositivity at baseline will be correlated
with study outcomes using an exploratory analysis. CMV is a
highly prevalent human herpes virus with CMV seropositivity
present in a large proportion of elderly patients. CMV-directed
cells increase with age, constituting a large proportion of the
total CD8+ T cell pool in elderly individuals [27]. T cell
responses to CMV are restricted to a limited number of epitopes,
resulting in progressive, prolonged oligoclonal expansion of
CMV-specific CD8+ T cells in a process known as memory
inflation [28]. We have previously shown that individuals who
are seropositive have a much higher proportion of CD8+
TEMRA cells and have a greater risk of heart attacks [7,29].
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Clinical Outcomes and Adverse Events
Major clinical events will be measured for 12 months from the
start of treatment. All-cause death, MI, and stroke will be
presented as a composite outcome—major adverse cardiac and
cerebrovascular events (MACCE)—and also reported separately.
All AEs, including those considered related and unrelated to
the intervention, will be recorded and reported from the time
of randomization for 12 months or until a patient has completed
all trial activities.
Study Setting
The trial aims to recruit 90 patients. All patients will be
recruited, treated, and followed up at a single site: The James
Cook University Hospital, Middlesbrough, UK. Blood samples
will be analyzed at site laboratories and, where specialist
equipment and expertise are required, will be transported to the
Institute of Genetic Medicine, Newcastle University, UK, for
analysis.
Study Visits and Assessments
Following baseline assessment and initiation of
treatment—placebo or TA-65MD—patients in both groups will
be followed up at 1 month, 3 months, 6 months, 9 months, and
12 months (see Table 1). At each visit, drug adherence will be
assessed and the patient will be evaluated for AEs.
Inclusion and Exclusion Criteria
Textbox 1 lists the criteria informing the eligibility or exclusion
of patients for the trial.
Textbox 1. Inclusion and exclusion criteria.
Inclusion criteria—patients will be eligible for the trial if they:
• Provide written informed consent
• Are male or female, aged 65 years or over, with an index presentation of an acute coronary syndrome (ACS)* within the previous 6 months
• Have successfully completed revascularization** or are being managed medically following ACS
• Have angiographic evidence of coronary heart disease: at least one major epicardial vessel stenosis ≥70%
• Are recruited more than 24 hours after presentation with the index ACS event
*ACS defined as either a non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI)
**Percutaneous coronary intervention or angioplasty, eligible the following day, or coronary artery bypass grafting, eligible 3 months following
surgery
Exclusion criteria—patients will be excluded from the trial if they:
• Have any disorder associated with immunological dysfunction (ie, acute or chronic inflammatory or neoplastic coexisting disease, known positive
serology for HIV, or hepatitis)
• Are clinically unstable (ie, hemodynamically unstable, cardiogenic shock, or unconscious)
• Have severe, uncontrolled hypertension (blood pressure [BP] >170/110 mmHg or ambulatory BP of 150/95 mmHg)
• Have a severe comorbidity that has impact on outcome over the next 2 years
• Are taking immunosuppressants
• Have a known malignancy
• Currently use a nutritional supplement derived from the roots of the
Astragalus
species
• Have a previous known substance addiction
• Have insulin-dependent diabetes
• Are judged by the investigator that they should not participate in the study, for example, on the basis of previous serious psychiatric illness or
are unlikely to comply with study procedures, restrictions, and requirements
• Have participated in any other interventional medicinal study in the past 6 months
Trial Procedures
Screening, Recruitment, and Consent of Participants
Potential participants will be identified by the clinical team
following admission to hospital with ACS and having agreed
to undergo coronary angiography or having already had an
angiography that confirms CHD. Patients may also be identified
following discharge. Potentially eligible participants will be
invited to participate by a delegated member of the study team.
The trial will be explained by the clinical research team and,
after time for questions, written consent will be sought from
the patient. Written informed consent will be obtained prior to
any trial specific procedures and prior to randomization. There
will be additional consent for storage of blood samples for up
to 5 years for future use in ancillary studies. Patients have the
right to withdraw from the trial at any time and without
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providing a reason. With the explicit consent of patients, general
practitioners will be informed of their participation.
Eligibility Assessment
Following consent, the principal investigator or a subinvestigator
on the delegation log will confirm the patient’s eligibility.
Patients who do not meet trial eligibility criteria prior to
randomization will be considered a screen failure and withdrawn
from the trial with no further data collected.
Randomization
Randomization will be performed using the Sealed Envelope
Ltd system with a minimization scheme to ensure patients
randomized to each group are comparable at baseline. The
minimization scheme will account for (1) gender (male or
female), (2) type of ACS (ST elevation myocardial infarction
[STEMI] or non-ST elevation myocardial infarction [NSTEMI]),
and (3) CD8+ TEMRA (high >45% or low ≤45%) at baseline.
Eligible patients will be randomized by delegated and trained
members of the research team at each center using the 24-hour,
central, secure, web-based randomization system with concealed
allocation. Eligible patients will be randomized in a 1:1 ratio
to receive TA-65MD (intervention under study) or placebo
(control arm).
Blinding
Assignment to either the TA-65MD or placebo groups will be
blinded to the patient, treating clinicians, and the clinical
research team, including the pharmacy, research nurses,
echocardiogram assessors, laboratory staff, and the chief
investigator. Blinding will be maintained in the randomization
system, the electronic case report forms (eCRFs), and on
investigational medicinal product (IMP) labels. All members
of the Newcastle Clinical Trial Unit (NCTU) and the statistics
team will be blinded, with the exception of the trial data manager
to enable reporting to the independent data monitoring
committee as appropriate. The IMP will be labeled using a
unique identification code, which will be linked to the study
randomization system. TA-65MD and its matched placebo will
be identical and presented in the same packaging to ensure
blinding of the IMP.
Unblinding
Unblinding should not occur except in the case of medical
emergencies, where the appropriate management of the patient
requires the knowledge of the randomization allocation. To
avoid unnecessary unblinding, it will be assumed that the patient
is on active treatment within the trial. The Sealed Envelope Ltd
online web-based randomization service will be used for
emergency unblinding. The primary trial analysis will be
performed prior to unblinding. All patients will be informed of
which arm they were assigned to, once analysis of the trial data
is complete.
Study Intervention
Intervention Under Study: TA-65MD
TA-65MD is marketed as a dietary supplement. The active
ingredient of TA-65MD is 1.8% CAG, isolated from roots of
the Astragalus species. The active ingredient has been identified
in an empirical screen of traditional Chinese medicine plant
extracts and compounds. TA-65MD is an activator of
telomerase, an enzyme whose actions protect the ends of
chromosomes from shortening associated with repeated cellular
replication. Patients allocated to the intervention will be given
8 mg of TA-65MD twice daily.
Control Arm: Placebo
The matched placebo has been manufactured to ensure that it
is consistent with TA-65MD in appearance, taste and smell,
labeling, packaging, and batch number. Patients allocated to
the placebo group will be given this twice daily.
Safety Data
Overview
An independent expert panel has determined TA-65MD to be
Generally Recognized As Safe (GRAS) for use in a medical
food under the provisions of the Federal Food, Drug, and
Cosmetic Act, administered by the US Food and Drug
Administration. T.A. Sciences, Inc, provided extensive animal
and human clinical data to support the status of GRAS. The
safety of TA-65MD has been assessed in an observational study
of 114 adults over the course of 1 year [30]. At doses up to 50
mg per day there were no AEs reported for TA-65MD. Safety
was also assessed in a randomized, placebo-controlled study
involving 117 adult volunteers over the course of 1 year, with
no toxicities detected in the liver, kidneys, and metabolic
functions as assessed by biochemical markers [29]. An
anticipated risk for the use of TA-65MD relates to its ability to
activate telomerase. This is the subject of scientific conjecture
in consideration of its relationship to cancer [31,32]. An in vitro
assay testing the telomerase-activating potency of TA-65 (ie,
CAG not in capsules) in Medical Research Council cell strain-5
(MRC-5) fibroblasts suggested there was dose-related TA (Sierra
Sciences Labs). While telomerase activation has been observed,
TA-65MD does not increase the lifespan of cells. In fact, the
preliminary observation of a controlled in vivo cancer study
using 5 mL/kg of TA-65 (ie, CAG not in capsules) or sham drug
administered by oral gavage for up to 40 days in mice
xenografted with four different human tumors—lung (H460),
colon (HT29), breast (MDA-MB-435), and prostate
(PC3)—suggests a trend toward tumor growth retardation in
two cancer types; as well, there was no statistically significant
adverse effects on body weight or tumor size for any of the cell
lines nor on the growth rate of the tumors (internal T.A. Sciences
document, 2008). Given that the population under study in the
TACTIC trial are elderly with ACS, and that there were no data
on the impact of the drug on the outcomes or population, we
chose to conduct the trial using a conservative dose of 8 mg
twice daily.
Known Side Effects
TA-65MD may interfere with medications that suppress the
immune system and may also affect blood sugar and blood
pressure. In an observational study, two subjects self-reported
an “anxious” feeling shortly after voluntarily increasing their
daily consumption of TA-65MD to 100 mg/day—a self-imposed
choice without physician approval at a consumption level two
times above the intended dose for this observational study; the
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feelings resolved in both subjects when daily consumption was
returned to 50 mg/day.
Administration and Adherence
Participants may begin taking the IMP immediately following
the completion of all baseline assessments, confirmation of
eligibility, and randomization. A dose of 8 mg of TA-65MD
(T.A. Sciences) or matched placebo will be taken as 1 × 8-mg
capsule twice daily (ie, morning and evening). Participants will
take the allocated IMP until the end of follow-up at 12 months.
Patients will be prescribed IMP following randomization and
at 1, 3, 6, and 9 months following the start of the intervention.
Returned capsules at each visit will be used to calculate the
adherence for each participant. Concomitant medications will
also be reviewed and documented at each visit.
Withdrawal of Participants
Participants will be made aware of their right to withdraw from
the trial at any time for any reason and without giving a reason.
Participants will be withdrawn from the trial by the clinical
team for any of the following reasons:
1. Intercurrent illness means the participant is no longer able
to complete study procedures.
2. The patient suffers unacceptable side effects caused by the
study drug.
3. Suspected unexpected serious adverse reactions occur.
The investigator can withdraw participants in the event of any
reason that would compromise participant safety or the validity
of the results. Data and blood samples collected up to the point
of withdrawal will be kept and used in the analysis of the trial
unless the participant explicitly requests for these to be removed.
Pharmacovigilance
All AEs will be recorded in the participants’ medical notes and
on the eCRFs. AEs will be recorded from the day of
randomization until the last visit or until withdrawal, with the
exception of those considered related to the IMP, which will be
followed until resolution, a stable outcome, or death. All AEs
are assessed for severity, causality, expectedness, and
seriousness by an investigator; all are reviewed by the
Independent Data Monitoring and Ethics Committee (IDMEC).
In accordance with current legislation, AEs will, where
necessary, undergo expedited reporting to the sponsor and to
the Medicines and Healthcare products Regulatory Agency
(MHRA) within the required timelines.
Statistical Considerations
Overview
A pragmatic decision was taken to recruit and analyze data on
90 patients: 45 in each group. This sample size is the minimum
conventional threshold for making parameter estimates in pilot
studies [33]. The parameter estimates in this trial will be used
to inform a large, multicenter clinical trial.
Data Management
Study data are recorded in each patient’s medical notes before
being recorded onto eCRFs, which are developed and managed
by the NCTU. The eCRF has been built using the Red Pill
system supplied by Sealed Envelope Ltd. Data entered onto the
eCRF must be consistent with the information in the medical
notes. Patients are identified using a unique study ID; all data
passed to the NCTU will have patient identifiers removed, with
the exception of date of birth, gender, ethnicity, and study ID.
Data cleaning is provided by staff within the NCTU.
Statistical Analysis
Primary analysis will follow intention-to-treat principles with
patient data analyzed according to randomization and
irrespective of intervention received; other analysis groups, such
as per-protocol groups, may be considered subsequently. Every
effort will be made to retain and include all patients who are
part of the trial.
Data will be summarized by study group. Mean or median will
summarize continuous variables, whereas number and
percentage will be used to summarize categorical variables. A
general linear model will be used to analyze the primary
outcome considering all covariates used in the randomization
scheme. Similar methods will be used to analyze all continuous
secondary outcomes. Data of other types will be analyzed using
generalized linear models with appropriate distributions.
The numbers of MACCE after 12 months will be compared
between arms by the use of standardized rates (eg, by
consideration of the number of events per patient month in each
arm). Impact of missing data will be explored by tabulating the
proportion of missing data in each arm. A full statistical analysis
plan will be developed for the outcome measures and agreed
upon with the IDMEC and the chief investigator prior to any
analysis being undertaken.
Trial Governance
The trial is sponsored by South Tees Hospitals National Health
Service (NHS) Foundation Trust and funded by T.A. Sciences,
Inc, New York, USA. The trial is being run in collaboration
with the NCTU at Newcastle University. The sponsor and funder
were not involved in the trial design. The sponsor has delegated
the trial design; collection, management, analysis, and
interpretation of data; report writing; and publications to the
chief investigator and coinvestigators. The trial is overseen by
the Trial Steering Committee, which meets every 6 months and
includes an independent chair and two other independent
members, one of whom is a patient. In addition, the trial includes
the IDMEC, which meets every 6 months and oversees all
ethical and safety issues in accordance with a study-specific
DAMOCLES (Data Monitoring Committees: Lessons, Ethics,
and Statistics) charter. All members are independent of the study
team, although the trial manager, chief investigator, and some
other members of the Trial Management Group attend the open
sessions in order to inform the committee about the trial
progress. The IDMEC makes recommendations to the Trial
Steering Committee. The day-to-day supervision of the trial
will be the responsibility of the Trial Management Group, who
report to the Trial Steering Committee.
Dissemination and Publications Policy
The trial will be published in peer-reviewed journals following
the end of the trial, and the data will be presented at national
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and international meetings. We do not intend to use professional
writers. Results of the trial will also be reported to the funder,
sponsor, and the Research Ethics Committee within one year
after the end of the trial. Trial participants will be informed
about the trial results and their treatment allocation at the end
of the trial, including a lay summary. The datasets analyzed
during this study are available from the corresponding author
on reasonable request.
Results
The study received NHS ethics approval on August 9, 2018;
MHRA approval on October 19, 2018; and NHS Health
Research Authority approval on October 22, 2018. The trial
began recruiting participants in January 2019 and completed
recruitment in March 2020; the trial is due to report results in
2021.
During the COVID-19 pandemic, all patients will have their
visits carried out remotely. Primary and secondary outcome
measures that are not able to be carried out remotely will occur
later than planned, on-site, as soon as it is safe for the patients
to do so and when laboratories are able to process and analyze
trial samples. Measures of blood pressure and blood glucose
will be undertaken by patients who have not yet attended the
site for their 6-month visit. Portable blood pressure monitors
and blood glucose monitors will be sent to those patients to be
used to record their results at home when required as per the
schedule of events for the duration of the pandemic. Some
patients may require continuation of the IMP beyond 12 months
to enable them to attend the hospital for their final trial visit
assessments. The 6-month and 12-month visits will occur as
soon as it is safe for this group of patients to attend the hospital
and when the trial laboratories are able to accommodate
processing and analysis of trial samples.
Discussion
ACS, the acute manifestation of atherosclerosis, is a leading
cause of mortality and morbidity. Age is an independent risk
factor for adverse cardiovascular outcomes after ACS, and this
is likely related to upregulation of the inflammatory response
that occurs with aging. Improvements in cardiovascular
outcomes over the last two decades have been realized mainly
in younger patients [34]. There remains an unmet need for novel
therapeutic approaches in older patients following ACS [35,36].
The CANTOS (Canakinumab Anti-Inflammatory Thrombosis
Outcomes Study) trial has provided strong evidence for the
critical role of inflammation in atherosclerosis by showing that
canakinumab—a human monoclonal anti-IL-1β antibody—led
to a reduction in major cardiovascular events independent of
lipid-level lowering [4]. Canakinumab was associated with a
higher incidence of nonfatal infection, potentially limiting its
use in older patients with CHD.
TA-65MD, the only available human telomerase activator, has
been shown to increase TL in human subjects. We hypothesize
that maintaining and/or lengthening telomeres can reduce T cell
immunosenescence, thus reducing their proinflammatory effects.
Telomerase has also been shown to have telomere-independent
properties in vitro, namely, a protective effect in cells under
oxidative stress and an ability to regulate FMD in the human
microvasculature.
The proposed pilot trial in older patients with CHD will provide
findings not previously investigated outside in vitro or
preclinical models, which will substantially enhance our
understanding of telomerase activators in this population and
their potential for benefit. The double-blind, randomized,
placebo-controlled design of the TACTIC trial will provide the
gold standard for evaluating signs of efficacy of TA-65MD.
Should the results indicate reduced frequency of
immunosenescent CD8+ T cells and improvements in TL as
well as endothelial function, we will aim to follow up with a
larger, multicenter efficacy trial in patients to determine if
TA-65MD is beneficial in the treatment of CHD.
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